HomeBUSINESS
BUSINESS

Daiichi Sankyo to Shed Non-Cancer R&D Costs, Allocate More Resources to Oncology: CEO
(Dec.14.2017)

Daiichi Sankyo CEO Joji Nakayama
Daiichi Sankyo is re-allocating its R&D investments as the company works to expedite the development of its key oncology candidates including HER2-targeting antibody drug conjugate (ADC) DS-8201, Chairman and CEO Joji Nakayama revealed ...
(LOG IN FOR FULL STORY)